Please provide a high-quality Persian translation of the following text, tailored for…
- User
Please provide a high-quality Persian translation of the following text, tailored for PhD graduates in medical sciences. You are absolutely free to change the sentence structure, vocabulary, and grammar as you wish for the best translation fit. Please adhere to the following guidelines:
- Accuracy: Ensure grammatical precision and technical accuracy, particularly regarding medical terminology.
- Fluency: Aim for natural language flow that sounds authentic to native Persian speakers in academic medical contexts.
- Register: Maintain a formal academic tone appropriate for postgraduate-level medical professionals.
- Clarity: Prioritize unambiguous communication of complex medical concepts.
- Cultural adaptation: o Adapt any culture-specific references or idioms to Persian equivalents where appropriate. o Note any cultural nuances relevant to the Iranian medical context.
- Restructuring: If necessary, rephrase or reorder sentences to enhance coherence and logical flow in Persian.
- Consistency: Maintain consistent terminology and style throughout the translation.
- To improve the translation, you can use literary patterns and vocabulary found in Persian scientific literature.
- References: If the original text includes citations or references, ensure they are formatted according to Persian academic conventions.
- If you don't think there is a suitable Persian equivalent for an English scientific phrase, don't translate it. Your expertise in both the Persian language and medical sciences is crucial for this task. The goal is a translation that conveys the original meaning accurately and reads as if it were originally written in Persian for an advanced medical audience. Feel free to modify the language structure, vocabulary, and grammar as needed to achieve the most natural and effective translation in Persian.
"The remission status and tumor bulk before CAR-T cell infusion significantly impact outcomes. High tumor volume, indicated by the sum of product diameters (SPD) or elevated LDH levels, is a negative prognostic factor. Disease control prior to CAR-T cell infusion is critical, and patients with rapidly progressing disease often do not respond well to bridging therapy, a necessary step due to delays in CAR-T cell production."
- Assistant
وضعیت بهبودی و حجم تومور قبل از انفوزیون سلولهای CAR-T بهطور قابلتوجهی بر نتایج تأثیر میگذارد. حجم بالای تومور، که با مجموع قطرهای حاصلضرب (SPD) یا افزایش سطح LDH نشان داده میشود، یک عامل پیشآگهی منفی محسوب میشود. کنترل بیماری پیش از انفوزیون سلولهای CAR-T حیاتی است و بیمارانی با بیماری بهسرعت پیشرونده اغلب به bridging therapy—که بهدلیل تأخیر در تولید سلولهای CAR-T یک مرحله ضروری است—پاسخ مطلوبی نمیدهند.